We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Topic: Renal and Urogenital Subtopic: Renal and Urogenital (all Subtopics) Disease: Renal
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Treatment of kidney disease accounts for a significant proportion of NHS spending. Transplantation is the best treatment for kidney failure, in terms of length and quality of life. It is also more cost-effective than dialysis. However, most transplants fail after 10-12 years and patients have to go back onto dialysis, placing a considerable burden on the NHS. Damage by the immune system, called 'chronic rejection' accounts for 50% of failing transplants and it is now possible to identify patients at risk by screening for a biomarker of chronic rejection called HLA antibodies (found in the blood). All transplant units in the UK can do this, but routine screening of patients has not been adopted because it is not clear how best to treat patients with antibodies. This study will test a screening and treatment protocol for HLA antibodies. The aim is to reduce transplant failure rates over 3 years.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2014 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/24447519 protocol2019 Protocol article in https://www.ncbi.nlm.nih.gov/pubmed/31383029 updated protocol and statistical analysis plan (added 07/08/2019)2016 Abstract results in https://bts.org.uk/wp-content/uploads/2016/09/BTS_Abstract_pdf_2016.pdf (added 18/11/2021)2023 Results article in https://pubmed.ncbi.nlm.nih.gov/36684392/ (added 24/01/2023)
You can take part if:
You may not be able to take part if:
1. Recipient requiring HLA desensitisation to remove antibody for a positive XM transplant2. Recipient known already to have HLA antibody who has received specific intervention for that antibody or for CAMR / chronic rejection3. Recipient of additional solid organ transplants (e.g. pancreas, heart, etc).4. History of malignancy in previous 5 years (excluding non-melanomatous tumours limited to skin)5. HBsAg+,HBcAb+, HepC+ or HIV+ recipient (on test performed within previous 5 years)6. History of acute rejection requiring escalation of immunosuppression in the 6 months prior to screening.7. History of an ongoing or previous infection (no time limit) that would prevent optimization of immunosuppression, including ocular Herpes simplex.8. Known hypersensitivity to any of the IMPs9. Known hereditary disorders of carbohydrate metabolism10. Patient enrolled in any other studies involving administration of another IMP at time of recruitment11. Pregnancy or breastfeeding females (based on verbal history of recipient)12. Pre-menopausal females who refuse to consent to using suitable methods of contraception throughout the trial.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Prof
Anthony
Dorling
-
anthony.dorling@kcl.ac.uk
The study is sponsored by King's College London (UK) and funded by NIHR (UK) - Efficacy and Mechanism Evaluation; Grant Codes: 11/100/34.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Or CPMS 13990
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
